PITTSBURGH, July 27, 2021 /PRNewswire/ -- Viatris
(NASDAQ: VTRS) today announced that the U.S. District Court for the
District of Kansas granted Mylan's
motion to dismiss in a lawsuit brought against it and Pfizer by KPH
Healthcare Services, Inc. (KPH) on behalf of an asserted class of
direct purchasers of EpiPen® products. The court agreed
with the company's argument that KPH lacked the legal standing to
assert the claims in its lawsuit and dismissed the case in its
entirety with an option for KPH to file a limited amended complaint
within 30 days.
The company is pleased with the Court's decision, as it has
always maintained that its actions were completely lawful and
pro-competitive. The company will continue to defend itself
vigorously should there be any further proceedings in the case.
About Viatris
Viatris Inc. (NASDAQ: VTRS) is a new kind of healthcare company,
empowering people worldwide to live healthier at every stage of
life. We provide access to medicines, advance sustainable
operations, develop innovative solutions and leverage our
collective expertise to connect more people to more products and
services through our one-of-a-kind Global Healthcare
Gateway®. Formed in November
2020, Viatris brings together scientific, manufacturing and
distribution expertise with proven regulatory, medical and
commercial capabilities to deliver high-quality medicines to
patients in more than 165 countries and territories. Viatris'
portfolio comprises more than 1,400 approved molecules across a
wide range of therapeutic areas, spanning both non-communicable and
infectious diseases, including globally recognized brands, complex
generic and branded medicines, a growing portfolio of biosimilars
and a variety of over-the-counter consumer products. With a global
workforce of approximately 45,000, Viatris is headquartered in the
U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at
viatris.com and investor.viatris.com, and connect with us on
Twitter at @ViatrisInc, LinkedIn and YouTube.
Forward-Looking Statements
This press release includes
statements that constitute "forward-looking statements." These
statements are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Such forward
looking statements may include statements about the outcome of
litigation, and that the Company will continue to defend itself
vigorously should there be any further proceedings in the case.
Because forward-looking statements inherently involve risks and
uncertainties, actual future results may differ materially from
those expressed or implied by such statements. Factors that could
cause or contribute to such differences include, but are not
limited to: the scope, timing and outcome of these or any other
ongoing legal proceedings and the impact of any such proceedings;
the potential impact of public health outbreaks, epidemics and
pandemics, including the ongoing challenges and uncertainties posed
by the COVID-19 pandemic; the integration of Mylan N.V. and Pfizer
Inc.'s Upjohn business (the "Upjohn Business"), which combined to
form Viatris (the "Combination") and the implementation of our
global restructuring initiatives being more difficult, time
consuming or costly than expected, or being unsuccessful; the
ability to achieve expected benefits, synergies and operating
efficiencies in connection with the Combination or its
restructuring initiatives within the expected timeframe or at all;
actions and decisions of healthcare and pharmaceutical regulators;
changes in healthcare and pharmaceutical laws and regulations in
the U.S. and abroad; any regulatory, legal or other impediments to
Viatris' ability to bring new products to market, including but not
limited to "at-risk" launches; Viatris' or its partners' ability to
develop, manufacture and commercialize products; the scope, timing
and outcome of any ongoing legal proceedings and the impact of any
such proceedings; any significant breach of data security or data
privacy or disruptions to our information technology systems; risks
associated with international operations, including our operations
in China; the ability to protect
intellectual property and preserve intellectual property rights;
changes in third-party relationships; the effect of any changes in
Viatris' or its partners' customer and supplier relationships and
customer purchasing patterns; the impacts of competition; changes
in the economic and financial conditions of Viatris or its
partners; uncertainties and matters beyond the control of
management; and the other risks Viatris' filings with the
Securities and Exchange Commission. Viatris routinely uses its
website at investor.viatris.com as a means of disclosing material
information to the public in a broad, non-exclusionary manner for
purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris
undertakes no obligation to update these statements for revisions
or changes after the date of this release other than as required by
law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mylan-wins-dismissal-of-kansas-epipen-direct-purchaser-case-301341808.html
SOURCE Viatris Inc.